Soufflé Therapeutics closes oversubscribed $135 million Series B backed by Safar Partners
Soufflé Therapeutics closed an oversubscribed Series B financing of $135 million on Oct. 13, 2026. Safar Partners LLC participated as an existing investor in the round. Soufflé is an RNA therapies company developing cell-specific delivery technology for targeted medicines. Funds will advance three lead programs into cl